儿童瘤学中的化疗诱导骨质疏松症:病理生理学和治疗方法
Jakub Pobideł1, Julia Piekarz2, Natalia Picheta1
1Student Academic Group, Department of Clinical Oncology and Chemotherapy, Medical University, Lublin, Poland.
Pediatric endocrinology, diabetes, and metabolism
|February 16, 2026
概括
由于癌症治疗,青少年骨质疏松症是儿童癌症幸存者日益关注的问题. 早期的多学科干预对于管理骨质损失和改善长期健康至关重要.
科学领域:
- 儿科瘤学 儿科瘤学
- 骨的新陈代谢 骨的新陈代谢
- 癌症的生存率 癌症的生存率
背景情况:
- 儿童癌症疗法,如化疗和葡萄糖皮质类药物,会破坏骨发育.
- 积极的癌症治疗可以导致通过炎症,氧化应激,荷尔蒙缺陷和药物毒性导致骨质损失.
- 内分泌不全症,如低阴性和生长激素缺乏,进一步损害了儿童癌症患者的骨质积累.
研究的目的:
- 审查治疗诱导的癌症儿童骨损失的多因素病理生理学.
- 概述导致的因素,包括治疗毒性,荷尔蒙失衡和行为变化.
- 讨论儿童癌症幸存者的二次骨质疏松症的诊断挑战和潜在干预措施.
主要方法:
- 在儿科瘤学中对青少年骨质疏松症研究的文献综述.
- 分析驱动骨损失的机制,包括细胞和分子途径.
- 检查遗传因素,诊断复杂性以及当前/新兴干预措施.
主要成果:
- 癌症治疗会损害骨质母细胞的功能,并通过甲基和葡萄糖皮质激素等药物增强骨质母细胞生成.
- 内分泌病,营养缺陷,身体不活动和心理疲劳导致骨质损失.
- 遗传因素 (例如,LRP5,ESR1突变) 和诊断变异性使管理复杂化.
结论:
- 儿科癌症幸存者的二次骨质疏松症是由瘤,代谢,行为和遗传因素的复杂相互作用造成的.
- 早期识别和持续监测对于管理骨密度至关重要.
- 包括体力活动,营养,内分泌评估和双酸盐在内的多学科策略对于保持骨完整性和提高生活质量至关重要.
相关概念视频
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
256
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
718
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
718
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
284
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
335
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
335